Chugai partners with GHIT Chugai Pharmaceutical Company, Ltd.'s December 24 commitment to GHIT as a formal partner represents the company's fundamental belief in GHIT's vision and mission, as well as a substantive financial contribution to our work tackling neglected diseases that disproportionally affect the developing world.

How we assess impact Read about the four key ways we evaluate our impact: by measuring progress through product development milestones and Stage-Gates, as well as by quantifying our invested innovations, and through targeted case studies. See metrics of our progress to date.

Partnership-driven innovation: Events in London and Tokyo On November 1 and 11, GHIT held public events in Tokyo and London respectively, both featuring interactive panels with world renowned experts. The first was a symposium at the Japanese Society of Tropical Medicine and Japanese Association for International Health joint conference. The second, co-hosted with the Embassy of Japan in London.

GHIT Fund Partners Meeting 2015 The GHIT Fund will host its Annual Partners Meeting on June 5, 2015 in Tokyo. In cerebration of our 2nd institutional anniversary, we are inviting internationally renowned experts to discuss global health innovation. Registration begins March, 2015.

PATH Malaria Vaccine Initiative and Ehime University are working to fast-track the research and manufacture of a novel malaria vaccine candidate (Pf75) that aims to block malaria parasite transmission from humans to mosquitoes. The project addresses one of the main challenges in developing malaria transmission-blocking vaccines-that very few potential target antigens aimed at interrupting transmission have yet been developed. GHIT's investment enables the partnership to streamline Pf75 product development as a vaccine candidate for clinical studies with pre-specified Stage-Gates for each developmental phase.

A consortium including the European Vaccine Initiative, Germany; the Research Institute for Microbial Diseases at Osaka University, Japan; and the Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso aims to clinically test a novel malaria vaccine candidate (BK-SE36), which would primarily target young children, who account for most malaria deaths. The project builds on promising results of a previous clinical trial and aims to generate more safety and efficacy data. Partners will also conduct a follow-up study on Japanese men who have previously been immunized with the vaccine containing a different adjuvant (a substance that enhances a person´s response to the vaccine).

Upcoming

Save the Date! - 3rd Annual GHIT Anniversary event. Public registration opens in March.
Tokyo, June 5, 2015.

Recent

Closing the Global Health Divide through Partnership-Driven Innovation
London, November 11.

2nd Proposal Writing Seminar with Dr. Michael Kurilla.
Tokyo, November 2.

Global Health Innovation through Partnership panel at the joint meeting of the Japanese Society of Tropical Medicine and Japan Association of International Health.
Tokyo, November 1.

Old and New Challenges in Global Health seminar with Dr. Peter Piot, organized by the Global Leadership Program at the University of Tokyo.
Tokyo, October 30.

Global Health Forum 2014.
Tokyo, October 31.

GHIT CEO BT Slingsby interviewed by Toyo Keizai Online
December 18

Professor Peter Piot, 2014 TIME Person of the Year: "The Ebola Fighters"
December 12

The National Bureau of Asian Research interview with BT Slingsby: The Current Ebola Outbreak: Implications for Asia and Global Health Innovation
December 8

Devex Impact: How to forge successful R&D partnerships
November 21

BT Slingsby interviewed by the NIKKEI on Ebola,
October 29

Op-ed by BT Slingsby in the Asahi Shimbun,
October 19